Spark Therapeutics (ONCE) Price Target Cut to $53.00

Spark Therapeutics (NASDAQ:ONCE) had its price objective lowered by UBS Group from $80.00 to $53.00 in a research report sent to investors on Wednesday, www.benzinga.com reports. UBS Group currently has a neutral rating on the biotechnology company’s stock.

ONCE has been the subject of a number of other research reports. Credit Suisse Group raised their price target on shares of Spark Therapeutics from $75.00 to $98.00 and gave the stock an outperform rating in a research note on Monday, July 9th. ValuEngine upgraded shares of Spark Therapeutics from a buy rating to a strong-buy rating in a research note on Saturday, June 2nd. JPMorgan Chase & Co. raised their price target on shares of Spark Therapeutics from $60.00 to $63.00 and gave the stock a neutral rating in a research note on Tuesday, May 1st. Raymond James restated a buy rating on shares of Spark Therapeutics in a research note on Wednesday, May 23rd. Finally, Mizuho restated a buy rating and set a $91.00 price target on shares of Spark Therapeutics in a research note on Tuesday, May 1st. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and twelve have assigned a buy rating to the company’s stock. The company presently has an average rating of Hold and a consensus target price of $72.67.

Shares of Spark Therapeutics traded up $0.54, hitting $58.42, during mid-day trading on Wednesday, according to MarketBeat.com. The company had a trading volume of 622,029 shares, compared to its average volume of 1,039,851. Spark Therapeutics has a 12 month low of $41.06 and a 12 month high of $96.59. The stock has a market cap of $2.17 billion, a PE ratio of -7.66 and a beta of 2.39.



Spark Therapeutics (NASDAQ:ONCE) last released its earnings results on Tuesday, August 7th. The biotechnology company reported ($0.77) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by ($0.34). Spark Therapeutics had a negative net margin of 185.46% and a negative return on equity of 17.33%. The company had revenue of $25.19 million during the quarter, compared to the consensus estimate of $29.44 million. sell-side analysts predict that Spark Therapeutics will post -2.15 earnings per share for the current year.

Several large investors have recently bought and sold shares of ONCE. Sofinnova Ventures Inc bought a new position in shares of Spark Therapeutics in the first quarter valued at approximately $32,048,000. Rockefeller Capital Management L.P. bought a new position in shares of Spark Therapeutics in the first quarter valued at approximately $23,940,000. PointState Capital LP bought a new position in shares of Spark Therapeutics in the first quarter valued at approximately $15,895,000. Pinnacle Associates Ltd. bought a new position in shares of Spark Therapeutics in the first quarter valued at approximately $15,611,000. Finally, BlackRock Inc. raised its stake in shares of Spark Therapeutics by 8.7% in the second quarter. BlackRock Inc. now owns 2,869,232 shares of the biotechnology company’s stock valued at $237,459,000 after acquiring an additional 229,786 shares during the last quarter.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.

Further Reading: Short Selling

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Leave a Reply